Open AccessClinical factors affecting the survival of patients diagnosed with non-small cell lung cancer and metastatic malignant pleural effusion, treated with hyperthermic intrathoracic chemotherapy or chemical talc pleurodesis: a monocentric, prospective, randomized trial
Author(s) -
Athanassios Kleontas,
Antonia Sioga,
Niki Pandria,
Nikolaos Barbetakis,
Achilleas Lazopoulos,
Ioannis Katsikas,
Christos Asteriou,
Dimitrios Paliouras,
Efstathios Kamperis,
Dimitrios Ikonomou,
Theodora Papamitsou,
Dimitrios Filippou,
Chariklia Destouni,
Louiza Ikonomou,
Konstantinos Zarogoulidis,
Kostas Papagiannopoulos
Publication year - 2019
Publication title -
journal of thoracic disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.682
H-Index - 60
eISSN - 2077-6624
pISSN - 2072-1439
DOI - 10.21037/jtd.2019.05.25
Subject(s) - medicine , malignant pleural effusion , lung cancer , surgery , randomized controlled trial , pleurodesis , pleural effusion , prospective cohort study , chemotherapy
There is a plethora of treatment algorithms for managing patients with malignant pleural effusions (MPEs), sharing many common points and principles. Our study aims to compare hyperthermic intrapleural chemotherapy (HITHOC) and talc pleurodesis (TALC), as treatment options for patients with non-small cell lung cancer (NSCLC) and metastatic MPE.